Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?” about issues related to clinical trial consent documents, particularly as they relate to the lawsuit filed against the FDA by the Center for Responsible Science, clinical trial participants and the father of a deceased trial participant.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
People
Related News
May 8, 2026
In the News
Shannon Goff Kukulka Highlighted Across Media for Foley Arrival
Foley & Lardner LLP partner Shannon Goff Kukulka is featured across media for her recent arrival to the firm's Nashville office.
May 4, 2026
In the News
James Lundy Assesses SEC Disgorgement Issues in Key Supreme Court Case
Foley & Lardner LLP partner James Lundy assessed the U.S. Supreme Court’s consideration of SEC disgorgement powers in the Bloomberg Law article, “SEC Win on Core Enforcement Tool Would Still Leave Payback Gaps.”
May 1, 2026
In the News
Kathryn Trkla Shares Insights on Evolution of US Derivatives Law
Foley & Lardner LLP partner Kathryn Trkla spoke to John Lothian News to share insights from co-authoring the latest edition of Derivatives Regulation, the leading authority on U.S. derivatives law.